-
Left atrial appendage closure for stroke prevention in atrial fibrillation: current status and perspectives Eur. Heart J. (IF 37.6) Pub Date : 2024-07-19 Ulf Landmesser, Carsten Skurk, Apostolos Tzikas, Volkmar Falk, Vivek Y Reddy, Stephan Windecker
Atrial fibrillation (AF) is associated with an increased risk of stroke and systemic embolism, and the left atrial appendage (LAA) has been identified as a principal source of thromboembolism in these patients. While oral anticoagulation is the current standard of care, LAA closure (LAAC) emerges as an alternative or complementary treatment approach to reduce the risk of stroke or systemic embolism
-
Genetic testing in early-onset atrial fibrillation Eur. Heart J. (IF 37.6) Pub Date : 2024-07-19 Shinwan Kany, Sean J Jurgens, Joel T Rämö, Ingrid E Christophersen, Michiel Rienstra, Mina K Chung, Morten S Olesen, Michael J Ackerman, Elizabeth M McNally, Christopher Semsarian, Renate B Schnabel, Arthur A M Wilde, Emelia J Benjamin, Heidi L Rehm, Paulus Kirchhof, Connie R Bezzina, Dan M Roden, M Benjamin Shoemaker, Patrick T Ellinor
Atrial fibrillation (AF) is a globally prevalent cardiac arrhythmia with significant genetic underpinnings, as highlighted by recent large-scale genetic studies. A prominent clinical and genetic overlap exists between AF, heritable ventricular cardiomyopathies, and arrhythmia syndromes, underlining the potential of AF as an early indicator of severe ventricular disease in younger individuals. Indeed
-
Bleeding risk prediction after acute myocardial infarction-integrating cancer data: the updated PRECISE-DAPT cancer score Eur. Heart J. (IF 37.6) Pub Date : 2024-07-17 Mohamed Dafaalla, Francesco Costa, Evangelos Kontopantelis, Mario Araya, Tim Kinnaird, Antonio Micari, Haibo Jia, Gary S Mintz, Mamas A Mamas
Background and Aims This study assessed the impact of incorporating cancer as a predictor on performance of the PRECISE-DAPT score. Methods A nationally linked cohort of ST-elevation myocardial infarction patients between 1 January 2005 and 31 March 2019 was derived from the UK Myocardial Ischaemia National Audit Project and the UK Hospital Episode Statistics Admitted Patient Care registries. The primary
-
A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers Eur. Heart J. (IF 37.6) Pub Date : 2024-07-16 Richard T Carrick, Alessio Gasperetti, Alexandros Protonotarios, Brittney Murray, Mikael Laredo, Iris van der Schaaf, Dennis Dooijes, Petros Syrris, Douglas Cannie, Crystal Tichnell, Nisha A Gilotra, Chiara Cappelletto, Kristen Medo, Ardan M Saguner, Firat Duru, Robyn J Hylind, Dominic J Abrams, Neal K Lakdawala, Julia Cadrin-Tourigny, Mattia Targetti, Iacopo Olivotto, Maddalena Graziosi, Moniek Cox
Background and Aims Pathogenic desmoplakin (DSP) gene variants are associated with the development of a distinct form of arrhythmogenic cardiomyopathy known as DSP cardiomyopathy. Patients harbouring these variants are at high risk for sustained ventricular arrhythmia (VA), but existing tools for individualized arrhythmic risk assessment have proven unreliable in this population. Methods Patients from
-
Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study Eur. Heart J. (IF 37.6) Pub Date : 2024-07-12 You-Jung Choi, Jaehyun Lim, Sungho Bea, Jieun Lee, Jah Yeon Choi, Seung Young Rho, Dae-In Lee, Jin Oh Na, Hyung-Kwan Kim
Background and Aims Concerns about the safety of coronavirus disease 2019 (COVID-19) vaccines in patients with atrial fibrillation/flutter (AF/AFL) have arisen due to reports of thrombo-embolic events following COVID-19 vaccination in the general population. This study aimed to evaluate the risk of thrombo-embolic events after COVID-19 vaccination in patients with AF/AFL. Methods This was a modified
-
Randomized 20-year infancy-onset dietary intervention, life-long cardiovascular risk factors and retinal microvasculature Eur. Heart J. (IF 37.6) Pub Date : 2024-07-12 Oskari Repo, Markus Juonala, Harri Niinikoski, Suvi Rovio, Juha Mykkänen, Hanna Lagström, Carol Y Cheung, Dawei Yang, Hanna Vaahtoranta-Lehtonen, Antti Jula, Jaakko Nevalainen, Tapani Rönnemaa, Jorma Viikari, Olli Raitakari, Robyn Tapp, Katja Pahkala
Background and Aims Retinal microvasculature characteristics predict cardiovascular morbidity and mortality. This study investigated associations of lifelong cardiovascular risk factors and effects of dietary intervention on retinal microvasculature in young adulthood. Methods The cohort is derived from the longitudinal Special Turku Coronary Risk Factor Intervention Project study. The Special Turku
-
Coronary artery disease management in older adults: revascularization and exercise training Eur. Heart J. (IF 37.6) Pub Date : 2024-07-10 Rita Pavasini, Simone Biscaglia, Vijay Kunadian, Abdul Hakeem, Gianluca Campo
The mean age of patients with coronary artery disease (CAD) is steadily increasing. In older patients, there is a tendency to underutilize invasive approach, coronary revascularization, up-to-date pharmacological therapies, and secondary prevention strategies, including cardiac rehabilitation. Older adults with CAD commonly exhibit atypical symptoms, multi-vessel disease involvement, complex coronary
-
Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice Eur. Heart J. (IF 37.6) Pub Date : 2024-07-10 Luis R Lopes, Carolyn Y Ho, Perry M Elliott
Pathogenic variation in genes encoding proteins of the cardiac sarcomere is responsible for 30%–40% of cases of hypertrophic cardiomyopathy. The main clinical utility of genetic testing is to provide diagnostic confirmation and facilitation of family screening. It also assists in the detection of aetiologies, which require distinct monitoring and treatment approaches. Other clinical applications, including
-
Artificial intelligence-enhanced patient evaluation: bridging art and science Eur. Heart J. (IF 37.6) Pub Date : 2024-07-08 Evangelos K Oikonomou, Rohan Khera
The advent of digital health and artificial intelligence (AI) has promised to revolutionize clinical care, but real-world patient evaluation has yet to witness transformative changes. As history taking and physical examination continue to rely on long-established practices, a growing pipeline of AI-enhanced digital tools may soon augment the traditional clinical encounter into a data-driven process
-
Sex differences in treatment of familial hypercholesterolaemia: a meta-analysis Eur. Heart J. (IF 37.6) Pub Date : 2024-07-08 Iulia Iatan, Leo E Akioyamen, Isabelle Ruel, Amanda Guerin, Lindsay Hales, Thais Coutinho, Liam R Brunham, Jacques Genest
Background and Aims Familial hypercholesterolaemia (FH) is a highly prevalent monogenic disorder characterized by elevated LDL cholesterol (LDL-C) levels and premature atherosclerotic cardiovascular disease. Sex disparities in diagnosis, lipid-lowering therapy, and achieved lipid levels have emerged worldwide, resulting in barriers to care in FH. A systematic review was performed to investigate sex-related
-
Lumican promotes calcific aortic valve disease through H3 histone lactylation Eur. Heart J. (IF 37.6) Pub Date : 2024-07-08 Yuming Huang, Chunli Wang, Tingwen Zhou, Fei Xie, Zongtao Liu, Haiying Xu, Ming Liu, Shunshun Wang, Lanqing Li, Qingjia Chi, Jiawei Shi, Nianguo Dong, Kang Xu
Background and Aims Valve interstitial cells (VICs) undergo a transition to intermediate state cells before ultimately transforming into the osteogenic cell population, which is a pivotal cellular process in calcific aortic valve disease (CAVD). Herein, this study successfully delineated the stages of VIC osteogenic transformation and elucidated a novel key regulatory role of lumican (LUM) in this
-
Atrial fibrillation burden: a new outcome predictor and therapeutic target Eur. Heart J. (IF 37.6) Pub Date : 2024-07-02 Nina Becher, Andreas Metzner, Tobias Toennis, Paulus Kirchhof, Renate B Schnabel
Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is not a dichotomous disease trait. Technological innovations enable long-term rhythm monitoring in many patients and can estimate AF burden. These technologies are already used to detect and monitor AF. This review describes the relation between AF burden and outcomes and potential effects of AF burden reduction. A lower AF burden
-
Wearable device-measured moderate to vigorous physical activity and risk of degenerative aortic valve stenosis Eur. Heart J. (IF 37.6) Pub Date : 2024-07-02 Ziang Li, Sijing Cheng, Bo Guo, Lu Ding, Yu Liang, Yinghan Shen, Jinyue Li, Yiqing Hu, Tianxin Long, Xinli Guo, Junbo Ge, Runlin Gao, Philippe Pibarot, Bin Zhang, Haiyan Xu, Marie-Annick Clavel, Yongjian Wu
Background and Aims Physical activity has proven effective in preventing atherosclerotic cardiovascular disease, but its role in preventing degenerative valvular heart disease (VHD) remains uncertain. This study aimed to explore the dose–response association between moderate to vigorous physical activity (MVPA) volume and the risk of degenerative VHD among middle-aged adults. Methods A full week of
-
Acute myocardial infarction and ischaemic stroke: differences and similarities in reperfusion therapies—a review Eur. Heart J. (IF 37.6) Pub Date : 2024-06-28 Lauranne Scheldeman, Peter Sinnaeve, Gregory W Albers, Robin Lemmens, Frans Van de Werf
Acute ST-elevation myocardial infarction (STEMI) and acute ischaemic stroke (AIS) share a number of similarities. However, important differences in pathophysiology demand a disease-tailored approach. In both conditions, fast treatment plays a crucial role as ischaemia and eventually infarction develop rapidly. Furthermore, in both fields, the introduction of fibrinolytic treatments historically preceded
-
Management of cardiac sarcoidosis Eur. Heart J. (IF 37.6) Pub Date : 2024-06-26 Rakesh Sharma, Vasileios Kouranos, Leslie T Cooper, Marco Metra, Arsen Ristic, Bettina Heidecker, John Baksi, Eleanor Wicks, Jose L Merino, Karin Klingel, Massimo Imazio, Christian de Chillou, Carsten Tschöpe, Petr Kuchynka, Steffen E Petersen, Theresa McDonagh, Thomas Lüscher, Gerasimos Filippatos
Cardiac sarcoidosis (CS) is a form of inflammatory cardiomyopathy associated with significant clinical complications such as high-degree atrioventricular block, ventricular tachycardia, and heart failure as well as sudden cardiac death. It is therefore important to provide an expert consensus statement summarizing the role of different available diagnostic tools and emphasizing the importance of a
-
Intravenous iron therapy results in rapid and sustained rise in myocardial iron content through a novel pathway Eur. Heart J. (IF 37.6) Pub Date : 2024-06-25 Mayra Vera-Aviles, Syeeda Nashitha Kabir, Akshay Shah, Paolo Polzella, Dillon Yee Lim, Poppy Buckley, Charlotte Ball, Dorine Swinkels, Hanke Matlung, Colin Blans, Philip Holdship, Jeremy Nugent, Edward Anderson, Michael Desborough, Stefan Piechnik, Vanessa Ferreira, Samira Lakhal-Littleton
Background and Aims Intravenous iron therapies contain iron–carbohydrate complexes, designed to ensure iron becomes bioavailable via the intermediary of spleen and liver reticuloendothelial macrophages. How other tissues obtain and handle this iron remains unknown. This study addresses this question in the context of the heart. Methods A prospective observational study was conducted in 12 patients
-
Cardiac shockwave therapy in addition to coronary bypass surgery improves myocardial function in ischaemic heart failure: the CAST-HF trial Eur. Heart J. (IF 37.6) Pub Date : 2024-06-20 Johannes Holfeld, Felix Nägele, Leo Pölzl, Clemens Engler, Michael Graber, Jakob Hirsch, Sophia Schmidt, Agnes Mayr, Felix Troger, Mathias Pamminger, Markus Theurl, Michael Schreinlechner, Nikolay Sappler, Elfriede Ruttmann-Ulmer, Wolfgang Schaden, John P Cooke, Hanno Ulmer, Axel Bauer, Can Gollmann-Tepeköylü, Michael Grimm
Background and Aims In chronic ischaemic heart failure, revascularisation strategies control symptoms but are less effective in improving left ventricular ejection fraction (LVEF). The aim of this trial is to investigate the safety of cardiac shockwave therapy (SWT) as a novel treatment option and its efficacy in increasing cardiac function by inducing angiogenesis and regeneration in hibernating myocardium
-
Lipid lowering for prevention of venous thromboembolism: a network meta-analysis Eur. Heart J. (IF 37.6) Pub Date : 2024-06-14 Ioannis T Farmakis, Konstantinos C Christodoulou, Lukas Hobohm, Stavros V Konstantinides, Luca Valerio
Background and Aims Studies have suggested that statins may be associated with reduced risk of venous thromboembolism (VTE). The aim of the current study was to assess the evidence regarding the comparative effect of all lipid-lowering therapies (LLT) in primary VTE prevention. Methods After a systematic search of PubMed, CENTRAL, and Web of Science up until 2 November 2022, randomized controlled trials
-
Non-coding RNA yREX3 from human extracellular vesicles exerts macrophage-mediated cardioprotection via a novel gene-methylating mechanism Eur. Heart J. (IF 37.6) Pub Date : 2024-06-12 Alessandra Ciullo, Liang Li, Chang Li, Kara Tsi, Colin Farrell, Matteo Pellegrini, Eduardo Marbán, Ahmed G E Ibrahim
Background and Aims Extracellular vesicles (EVs) secreted by cardiosphere-derived cells exert immunomodulatory effects through the transmission of small non-coding RNAs. Methods The mechanism and role of yREX3, a small Y RNA abundant in EVs in myocardial injury, was investigated. Results yREX3 attenuates cardiac ischaemic injury by selective DNA methylation. Synthetic yREX3 encapsulated in lipid nanoparticles
-
Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy Eur. Heart J. (IF 37.6) Pub Date : 2024-06-10 Daniel Gaudet, Susanne Greber-Platzer, Laurens F Reeskamp, Gabriella Iannuzzo, Robert S Rosenson, Samir Saheb, Claudia Stefanutti, Erik Stroes, Albert Wiegman, Traci Turner, Shazia Ali, Poulabi Banerjee, Tiera Drewery, Jennifer McGinniss, Alpana Waldron, Richard T George, Xue-Qiao Zhao, Robert Pordy, Jian Zhao, Eric Bruckert, Frederick J Raal
Background and Aims Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disorder characterized by severely elevated LDL cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease. In the pivotal Phase 3 HoFH trial (NCT03399786), evinacumab significantly decreased LDL-C in patients with HoFH. This study assesses the long-term safety and efficacy of evinacumab in adult and
-
Multiple arterial vs. single arterial coronary artery bypass grafting: sex-related differences in outcomes Eur. Heart J. (IF 37.6) Pub Date : 2024-05-31 Justin Ren, Andrea Bowyer, David H Tian, Colin Royse, Doa El-Ansary, Alistair Royse
Background and Aims Uncertainty exists over whether multiple arterial grafting has a sex-related association with survival after coronary artery bypass grafting. This study aims to compare the long-term survival of using multiple arterial grafting vs. single arterial grafting in women and men undergoing coronary artery bypass grafting. Methods The retrospective study used the Australian and New Zealand
-
Non-ST-elevation acute coronary syndromes with previous coronary artery bypass grafting: a meta-analysis of invasive vs. conservative management Eur. Heart J. (IF 37.6) Pub Date : 2024-05-28 Matthew Kelham, Rohan Vyas, Rohini Ramaseshan, Krishnaraj Rathod, Robbert J de Winter, Ruben W de Winter, Bjorn Bendz, Holger Thiele, Geir Hirlekar, Nuccia Morici, Aung Myat, Lampros K Michalis, Juan Sanchis, Vijay Kunadian, Colin Berry, Anthony Mathur, Daniel A Jones
Background and Aims A routine invasive strategy is recommended in the management of higher risk patients with non-ST-elevation acute coronary syndromes (NSTE-ACSs). However, patients with previous coronary artery bypass graft (CABG) surgery were excluded from key trials that informed these guidelines. Thus, the benefit of a routine invasive strategy is less certain in this specific subgroup. Methods
-
Risk of heart failure in inflammatory bowel disease: a Swedish population-based study Eur. Heart J. (IF 37.6) Pub Date : 2024-05-21 Jiangwei Sun, Jialu Yao, Ola Olén, Jonas Halfvarson, David Bergman, Fahim Ebrahimi, Annika Rosengren, Johan Sundström, Jonas F Ludvigsson
Background and Aims Dysregulation of inflammatory and immune responses has been implicated in the pathogenesis of heart failure (HF). But even if inflammation is a prerequisite for inflammatory bowel disease (IBD), little is known about HF risk in IBD. Methods In this Swedish nationwide cohort, patients with biopsy-confirmed IBD were identified between 1969 and 2017 [n = 81,749, Crohn’s disease (CD
-
Nocturnal heat exposure and stroke risk Eur. Heart J. (IF 37.6) Pub Date : 2024-05-21 Cheng He, Susanne Breitner, Siqi Zhang, Veronika Huber, Markus Naumann, Claudia Traidl-Hoffmann, Gertrud Hammel, Annette Peters, Michael Ertl, Alexandra Schneider
Background and Aims In recent decades, nighttime temperatures have increased faster than daytime temperatures. The increasing prevalence of nocturnal heat exposure may pose a significant risk to cardiovascular health. This study investigated the association between nighttime heat exposure and stroke risk in the region of Augsburg, Germany, and examined its temporal variations over 15 years. Methods
-
Catheter ablation for persistent atrial fibrillation: patterns of recurrence and impact on quality of life and health care utilisation Eur. Heart J. (IF 37.6) Pub Date : 2024-05-17 Rose Crowley, David Chieng, Hariharan Sugumar, Liang-Han Ling, Louise Segan, Jeremy William, Sandeep Prabhu, Aleksandr Voskoboinik, Geoffrey Wong, Joseph B Morton, Geoffrey Lee, Alex J McLellan, Michael Wong, Rajeev K Pathak, Laurence Sterns, Matthew Ginks, Prashanthan Sanders, Jonathan M Kalman, Peter M Kistler
Background and aims Patterns of atrial fibrillation (AF) recurrence post catheter ablation for persistent AF are not well described. This study aimed to describe the pattern of AF recurrence seen following catheter ablation for persistent AF (PsAF) and the implications for healthcare utilisation and quality of life. Methods This was a post-hoc analysis of the CAPLA study, an international, multi-centre
-
Cortico-limbic interactions and carotid atherosclerotic burden during chronic stress exposure Eur. Heart J. (IF 37.6) Pub Date : 2024-05-16 Charbel Gharios, Mandy M T van Leent, Helena L Chang, Shady Abohashem, David O’Connor, Michael T Osborne, Cheuk Y Tang, Audrey E Kaufman, Philip M Robson, Sarayu Ramachandran, Claudia Calcagno, Venkatesh Mani, Maria Giovanna Trivieri, Antonia V Seligowski, Sharon Dekel, Willem J M Mulder, James W Murrough, Lisa M Shin, Ahmed Tawakol, Zahi A Fayad
Background and Aims Chronic stress associates with cardiovascular disease, but mechanisms remain incompletely defined. Advanced imaging was used to identify stress-related neural imaging phenotypes associated with atherosclerosis. Methods Twenty-seven individuals with post-traumatic stress disorder (PTSD), 45 trauma-exposed controls without PTSD, and 22 healthy controls underwent 18F-fluorodeoxyglucose
-
Ticagrelor monotherapy for acute coronary syndrome: an individual patient data meta-analysis of TICO and T-PASS trials Eur. Heart J. (IF 37.6) Pub Date : 2024-05-16 Yong-Joon Lee, Sanghoon Shin, Sung Woo Kwon, Yongsung Suh, Kyeong Ho Yun, Tae Soo Kang, Jun-Won Lee, Deok-Kyu Cho, Jong-Kwan Park, Jang-Whan Bae, Woong Cheol Kang, Seunghwan Kim, Seung-Jun Lee, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Myeong-Ki Hong
Background and Aims In patients with acute coronary syndrome (ACS), dual antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor is recommended for 12 months after drug-eluting stent (DES) implantation. Monotherapy with a potent P2Y12 inhibitor after short-term DAPT is an attractive option to better balance the risks of ischaemia and bleeding. Therefore, this study evaluated the efficacy
-
Brugada syndrome in Japan and Europe: a genome-wide association study reveals shared genetic architecture and new risk loci Eur. Heart J. (IF 37.6) Pub Date : 2024-05-15 Taisuke Ishikawa, Tatsuo Masuda, Tsuyoshi Hachiya, Christian Dina, Floriane Simonet, Yuki Nagata, Michael W T Tanck, Kyuto Sonehara, Charlotte Glinge, Rafik Tadros, Apichai Khongphatthanayothin, Tzu-Pin Lu, Chihiro Higuchi, Tadashi Nakajima, Kenshi Hayashi, Yoshiyasu Aizawa, Yukiko Nakano, Akihiko Nogami, Hiroshi Morita, Seiko Ohno, Takeshi Aiba, Christian Krijger Juárez, John Mauleekoonphairoj, Yong
Background and Aims Brugada syndrome (BrS) is an inherited arrhythmia with a higher disease prevalence and more lethal arrhythmic events in Asians than in Europeans. Genome-wide association studies (GWAS) have revealed its polygenic architecture mainly in European populations. The aim of this study was to identify novel BrS-associated loci and to compare allelic effects across ancestries. Methods A
-
Mitral valve prolapse: arrhythmic risk during pregnancy and postpartum Eur. Heart J. (IF 37.6) Pub Date : 2024-05-14 Avi Sabbag, Eivind W Aabel, Anna Isotta Castrini, Konstantinos C Siontis, Mikael Laredo, Jacky Nizard, Guillaume Duthoit, Samuel Asirvatham, Ojasay Sehrawat, Feddo P Kirkels, Philippe J van Rosendael, Roy Beinart, Moshe Rav Acha, Petr Peichl, Han S Lim, Christian Sohns, Raphael Martins, Jonaz Font, Nguyen N K Truong, Mette Estensen, Kristina H Haugaa
Background and Aims Arrhythmic mitral valve prolapse (AMVP) is linked to life-threatening ventricular arrhythmias (VAs), and young women are considered at high risk. Cases of AMVP in women with malignant VA during pregnancy have emerged, but the arrhythmic risk during pregnancy is unknown. The authors aimed to describe features of women with high-risk AMVP who developed malignant VA during the perinatal
-
Periprocedural myocardial infarction after percutaneous coronary intervention and long-term mortality: a meta-analysis Eur. Heart J. (IF 37.6) Pub Date : 2024-05-14 Luca Paolucci, Fabio Mangiacapra, Sara Sergio, Annunziata Nusca, Carlo Briguori, Emanuele Barbato, Gian Paolo Ussia, Francesco Grigioni
Background and Aims Conflicting data are available regarding the association between periprocedural myocardial infarction (PMI) and mortality following percutaneous coronary intervention. The purpose of this study was to evaluate the incidence and prognostic implication of PMI according to the Universal Definition of Myocardial Infarction (UDMI), the Academic Research Consortium (ARC)-2 definition
-
Three-dimensional cardiac magnetic resonance allows the identification of slow-conducting anatomical isthmuses in tetralogy of Fallot Eur. Heart J. (IF 37.6) Pub Date : 2024-05-11 Yoshitaka Kimura, Justin Wallet, Benjamin Bouyer, Monique R M Jongbloed, Robin Bertels, Mark G Hazekamp, Jean-Benoit Thambo, Xavier Iriart, Hubert Cochet, Frederic Sacher, Hildo J Lamb, Nico A Blom, Katja Zeppenfeld
Background and Aims Patients with repaired tetralogy of Fallot remain at risk of life-threatening ventricular tachycardia related to slow-conducting anatomical isthmuses (SCAIs). Preventive ablation of SCAI identified by invasive electroanatomical mapping is increasingly performed. This study aimed to non-invasively identify SCAI using 3D late gadolinium enhancement cardiac magnetic resonance (3D-LGE-CMR)
-
Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials Eur. Heart J. (IF 37.6) Pub Date : 2024-05-11 Sanjiv J Shah, Kavita Sharma, Barry A Borlaug, Javed Butler, Melanie Davies, Dalane W Kitzman, Mark C Petrie, Subodh Verma, Shachi Patel, Khaja M Chinnakondepalli, Mette N Einfeldt, Thomas J Jensen, Søren Rasmussen, Rabea Asleh, Tuvia Ben-Gal, Mikhail N Kosiborod
Background and Aims In the STEP-HFpEF trial program, treatment with semaglutide resulted in multiple beneficial effects in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). Efficacy may vary according to baseline diuretic use, and semaglutide treatment could modify diuretic dose. Methods In this pre-specified analysis of pooled data from the STEP-HFpEF and STEP-HFpEF-DM
-
Identification of three mechanistic pathways for iron-deficient heart failure Eur. Heart J. (IF 37.6) Pub Date : 2024-05-11 Milton Packer, Stefan D Anker, Javed Butler, John G F Cleland, Paul R Kalra, Robert J Mentz, Piotr Ponikowski
Current understanding of iron-deficient heart failure is based on blood tests that are thought to reflect systemic iron stores, but the available evidence suggests greater complexity. The entry and egress of circulating iron is controlled by erythroblasts, which (in severe iron deficiency) will sacrifice erythropoiesis to supply iron to other organs, e.g. the heart. Marked hypoferraemia (typically
-
Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial Eur. Heart J. (IF 37.6) Pub Date : 2024-05-09 P R D Clephas, V W Zwartkruis, J Malgie, M W F van Gent, H P Brunner-La Rocca, M K Szymanski, V P van Halm, M L Handoko, W Kok, F W Asselbergs, R van Kimmenade, O Manintveld, N M D A van Mieghem, S L M A Beeres, M C Post, C J W Borleffs, R Tukkie, A Mosterd, G C M Linssen, R F Spee, M E Emans, T D J Smilde, J van Ramshorst, C Kirchhof, F Feenema–Aardema, C A da Fonseca, M van den Heuve, R Hazeleger
Background and Aims In patients with chronic heart failure (HF), the MONITOR-HF trial demonstrated the efficacy of pulmonary artery (PA)-guided HF therapy over standard of care in improving quality of life and reducing HF hospitalizations and mean PA pressure. This study aimed to evaluate the consistency of these benefits in relation to clinically relevant subgroups. Methods The effect of PA-guided
-
Lower extremity arterial disease vs. coronary artery disease: mortality differences after revascularization Eur. Heart J. (IF 37.6) Pub Date : 2024-05-02 Mitsuyoshi Takahara, Yoshimitsu Soga, Osamu Iida
Background and Aims Patients undergoing revascularization for lower extremity arterial disease (LEAD) may face a higher risk of mortality than those with coronary artery disease (CAD). This study aimed to characterize the difference in mortality risk between patients undergoing revascularization for LEAD and CAD and identify associated factors. Methods The 1-year database of 10 754 patients undergoing
-
Embolic strokes of undetermined source: a clinical consensus statement of the ESC Council on Stroke, the European Association of Cardiovascular Imaging and the European Heart Rhythm Association of the ESC Eur. Heart J. (IF 37.6) Pub Date : 2024-04-30 George Ntaios, Helmut Baumgartner, Wolfram Doehner, Erwan Donal, Thor Edvardsen, Jeff S Healey, Bernard Iung, Hooman Kamel, Scott E Kasner, Eleni Korompoki, Babak B Navi, Christian Pristipino, Luca Saba, Renate B Schnabel, Emma Svennberg, Gregory Y H Lip
One in six ischaemic stroke patients has an embolic stroke of undetermined source (ESUS), defined as a stroke with unclear aetiology despite recommended diagnostic evaluation. The overall cardiovascular risk of ESUS is high and it is important to optimize strategies to prevent recurrent stroke and other cardiovascular events. The aim of clinicians when confronted with a patient not only with ESUS but
-
Long-term outcomes after hospitalization for atrial fibrillation or flutter Eur. Heart J. (IF 37.6) Pub Date : 2024-04-28 Linh Thi Hai Ngo, Yang Peng, Russell Denman, Ian Yang, Isuru Ranasinghe
Background and Aims Atrial fibrillation (AF) and flutter are common causes of hospitalizations but contemporary long-term outcomes following these episodes are uncertain. This study assessed outcomes up to 10 years after an acute AF or flutter hospitalization. Methods Patients hospitalized acutely with a primary diagnosis of AF or flutter from 2008–17 from all public and most private hospitals in Australia
-
Myocardial reperfusion injury exacerbation due to ALDH2 deficiency is mediated by neutrophil extracellular traps and prevented by leukotriene C4 inhibition Eur. Heart J. (IF 37.6) Pub Date : 2024-04-26 Kun Yang, Rifeng Gao, Hanchuan Chen, Jingjing Hu, Peng Zhang, Xiang Wei, Jiaran Shi, Yinyin Chen, Liwei Zhang, Juntao Chen, Yang Lyu, Zhen Dong, Wei Wei, Kai Hu, Yansong Guo, Junbo Ge, Aijun Sun
Background and Aims The Glu504Lys polymorphism in the aldehyde dehydrogenase 2 (ALDH2) gene is closely associated with myocardial ischaemia/reperfusion injury (I/RI). The effects of ALDH2 on neutrophil extracellular trap (NET) formation (i.e. NETosis) during I/RI remain unknown. This study aimed to investigate the role of ALDH2 in NETosis in the pathogenesis of myocardial I/RI. Methods The mouse model
-
Aspirin hypersensitivity: a practical guide for cardiologists Eur. Heart J. (IF 37.6) Pub Date : 2024-04-26 Silvia Grimaldi, Paola Migliorini, Ilaria Puxeddu, Roberta Rossini, Raffaele De Caterina
Aspirin has been known for a long time and currently stays as a cornerstone of antithrombotic therapy in cardiovascular disease. In patients with either acute or chronic coronary syndromes undergoing percutaneous coronary intervention aspirin is mandatory in a dual antiplatelet therapy regimen for prevention of stent thrombosis and/or new ischaemic events. Aspirin is also currently a first-option antithrombotic
-
Income variability and incident cardiovascular disease in diabetes: a population-based cohort study Eur. Heart J. (IF 37.6) Pub Date : 2024-04-26 Yong-Moon Mark Park, Jong-Ha Baek, Hong Seok Lee, Tali Elfassy, Clare C Brown, Mario Schootman, Marie-Rachelle Narcisse, Seung-Hyun Ko, Pearl A McElfish, Michael R Thomsen, Benjamin C Amick, Seong-Su Lee, Kyungdo Han
Background and Aims Longitudinal change in income is crucial in explaining cardiovascular health inequalities. However, there is limited evidence for cardiovascular disease (CVD) risk associated with income dynamics over time among individuals with type 2 diabetes (T2D). Methods Using a nationally representative sample from the Korean National Health Insurance Service database, 1 528 108 adults aged
-
Body mass index, waist circumference, and mortality in subjects older than 80 years: a Mendelian randomization study Eur. Heart J. (IF 37.6) Pub Date : 2024-04-16 Yuebin Lv, Yue Zhang, Xinwei Li, Xiang Gao, Yongyong Ren, Luojia Deng, Lanjing Xu, Jinhui Zhou, Bing Wu, Yuan Wei, Xingyao Cui, Zinan Xu, Yanbo Guo, Yidan Qiu, Lihong Ye, Chen Chen, Jun Wang, Chenfeng Li, Yufei Luo, Zhaoxue Yin, Chen Mao, Qiong Yu, Hui Lu, Virginia Byers Kraus, Yi Zeng, Shilu Tong, Xiaoming Shi
Background and Aims Emerging evidence has raised an obesity paradox in observational studies of body mass index (BMI) and health among the oldest-old (aged ≥80 years), as an inverse relationship of BMI with mortality was reported. This study was to investigate the causal associations of BMI, waist circumference (WC), or both with mortality in the oldest-old people in China. Methods A total of 5306
-
Coexisting atrial fibrillation and cancer: time trends and associations with mortality in a nationwide Dutch study Eur. Heart J. (IF 37.6) Pub Date : 2024-04-15 Qingui Chen, Nienke van Rein, Tom van der Hulle, Julius C Heemelaar, Serge A Trines, Henri H Versteeg, Frederikus A Klok, Suzanne C Cannegieter
Background and Aims Coexisting atrial fibrillation (AF) and cancer challenge the management of both. The aim of the study is to comprehensively provide the epidemiology of coexisting AF and cancer. Methods Using Dutch nationwide statistics, individuals with incident AF (n = 320 139) or cancer (n = 472 745) were identified during the period 2015–19. Dutch inhabitants without a history of AF (n = 320
-
Ischaemic stroke in women with atrial fibrillation: temporal trends and clinical implications Eur. Heart J. (IF 37.6) Pub Date : 2024-04-12 Konsta Teppo, K E Juhani Airaksinen, Jussi Jaakkola, Olli Halminen, Birgitta Salmela, Elis Kouki, Jari Haukka, Jukka Putaala, Miika Linna, Aapo L Aro, Pirjo Mustonen, Juha Hartikainen, Gregory Y H Lip, Mika Lehto
Background and Aims Female sex has been linked with higher risk of ischaemic stroke (IS) in atrial fibrillation (AF), but no prior study has examined temporal trends in the IS risk associated with female sex. Methods The registry-linkage Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) study included all patients with AF in Finland from 2007 to 2018. Ischaemic stroke rates and rate ratios were
-
Rescue of cardiac dysfunction during chemotherapy in acute myeloid leukaemia by blocking IL-1α Eur. Heart J. (IF 37.6) Pub Date : 2024-04-12 Xingliang Zhou, Yiwei Liu, Yi Shen, Lijun Chen, Wenting Hu, Yi Yan, Bei Feng, Li Xiang, Yifan Zhu, Chenyu Jiang, Zihao Dai, Xu Huang, Liwei Wu, Tianyu Liu, Lijun Fu, Caiwen Duan, Shuhong Shen, Jun Li, Hao Zhang
Background and Aims Patients with acute myeloid leukaemia (AML) suffer from severe myocardial injury during daunorubicin (DNR)-based chemotherapy and are at high risk of cardiac mortality. The crosstalk between tumour cells and cardiomyocytes might play an important role in chemotherapy-related cardiotoxicity, but this has yet to be demonstrated. This study aimed to identify its underlying mechanism
-
Atrial fibrillation: age at diagnosis, incident cardiovascular events, and mortality Eur. Heart J. (IF 37.6) Pub Date : 2024-04-09 Christian Paludan-Müller, Oliver B Vad, Niels K Stampe, Søren Z Diederichsen, Laura Andreasen, Laia M Monfort, Emil L Fosbøl, Lars Køber, Christian Torp-Pedersen, Jesper H Svendsen, Morten S Olesen
Background and Aims Patients with atrial fibrillation (AF) are at increased risks of cardiovascular diseases and mortality, but risks according to age at diagnosis have not been reported. This study investigated age-specific risks of outcomes among patients with AF and the background population. Methods This nationwide population-based cohort study included patients with AF and controls without outcomes
-
Use of new and emerging cancer drugs: what the cardiologist needs to know Eur. Heart J. (IF 37.6) Pub Date : 2024-04-09 Iacopo Fabiani, Michela Chianca, Alberto Aimo, Michele Emdin, Susan Dent, Antonella Fedele, Carlo Maria Cipolla, Daniela Maria Cardinale
The last decade has witnessed a paradigm shift in cancer therapy, from non-specific cytotoxic chemotherapies to agents targeting specific molecular mechanisms. Nonetheless, cardiovascular toxicity of cancer therapies remains an important concern. This is particularly relevant given the significant improvement in survival of solid and haematological cancers achieved in the last decades. Cardio-oncology
-
Catheter-based therapy for high-risk or intermediate-risk pulmonary embolism: death and re-hospitalization Eur. Heart J. (IF 37.6) Pub Date : 2024-04-04 Orly Leiva, Carlos Alviar, Sameer Khandhar, Sahil A Parikh, Catalin Toma, Radu Postelnicu, James Horowitz, Vikramjit Mukherjee, Allison Greco, Sripal Bangalore
Background and Aims Catheter-based therapies (CBTs) have been developed as a treatment option in patients with pulmonary embolism (PE). There remains a paucity of data to inform decision-making in patients with intermediate-risk or high-risk PE. The aim of this study was to characterize in-hospital and readmission outcomes in patients with intermediate-risk or high-risk PE treated with vs. without
-
Syphilis and cardiovascular risk: a Taiwanese registry Eur. Heart J. (IF 37.6) Pub Date : 2024-04-03 Victor Chien-Chia Wu, Jih-Kai Yeh, Shao-Wei Chen, Chia-Ling Wu, Yu-Sheng Lin, Michael Wu, Kai-Che Wei, Pao-Hsien Chu, Shang-Hung Chang, Yu-Tung Huang
Background and Aims Studies on the impact of syphilis on the cardiovascular system in large populations are limited. This study investigated the effects of syphilis on cardiovascular outcomes. Methods Medical records from 2010 to 2015 were retrieved from the Taiwan National Health Insurance Research Database, linked to the Notifiable Infectious Diseases database from the Taiwan Centers for Disease
-
Integration of a polygenic score into guideline-recommended prediction of cardiovascular disease Eur. Heart J. (IF 37.6) Pub Date : 2024-03-29 Ling Li, Shichao Pang, Fabian Starnecker, Bertram Mueller-Myhsok, Heribert Schunkert
Background and Aims It is not clear how a polygenic risk score (PRS) can be best combined with guideline-recommended tools for cardiovascular disease (CVD) risk prediction, e.g. SCORE2. Methods A PRS for coronary artery disease (CAD) was calculated in participants of UK Biobank (n = 432 981). Within each tenth of the PRS distribution, the odds ratios (ORs)—referred to as PRS-factor—for CVD (i.e. CAD
-
Patient–physician sex concordance and outcomes in cardiovascular disease: a systematic review Eur. Heart J. (IF 37.6) Pub Date : 2024-03-29 Lamia Harik, Ko Yamamoto, Takeshi Kimura, Lisa Q Rong, Birgit Vogel, Roxana Mehran, C Noel Bairey-Merz, Mario Gaudino
The sex disparity in outcomes of patients with cardiovascular disease is well-described and has persisted across recent decades. While there have been several proposed mechanisms to explain this disparity, there are limited data on female patient–physician sex concordance and its association with outcomes. The authors review the existing literature on the relationship between patient–physician sex
-
Artificial intelligence–based assessment of built environment from Google Street View and coronary artery disease prevalence Eur. Heart J. (IF 37.6) Pub Date : 2024-03-28 Zhuo Chen, Jean-Eudes Dazard, Yassin Khalifa, Issam Motairek, Sadeer Al-Kindi, Sanjay Rajagopalan
Background and Aims Built environment plays an important role in the development of cardiovascular disease. Tools to evaluate the built environment using machine vision and informatic approaches have been limited. This study aimed to investigate the association between machine vision–based built environment and prevalence of cardiometabolic disease in US cities. Methods This cross-sectional study used
-
Cardiac implantable electronic devices and bloodstream infections: management and outcomes Eur. Heart J. (IF 37.6) Pub Date : 2024-03-28 Tardu Özkartal, Andrea Demarchi, Giulio Conte, Damiano Pongan, Catherine Klersy, Maria Luce Caputo, Marco Bergonti, Enos Bernasconi, Valeria Gaia, Christopher B Granger, Angelo Auricchio
Background and Aims Bloodstream infection (BSI) of any cause may lead to device infection in cardiac implantable electronic device (CIED) patients. Aiming for a better understanding of the diagnostic approach, treatment, and outcome, patients with an implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy and defibrillator (CRT-D) hospitalized with BSI were investigated.
-
Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial Eur. Heart J. (IF 37.6) Pub Date : 2024-03-21 Daniel A Jones, Anne-Marie Beirne, Matthew Kelham, Lucinda Wynne, Mervyn Andiapen, Krishnaraj S Rathod, Tipparat Parakaw, Jessica Adams, Annastazia Learoyd, Kamran Khan, Thomas Godec, Paul Wright, Sotiris Antoniou, Andrew Wragg, Muhammad Yaqoob, Anthony Mathur, Amrita Ahluwalia
Background and Aims Contrast-induced nephropathy (CIN), also known as contrast-associated acute kidney injury (CA-AKI) underlies a significant proportion of the morbidity and mortality following coronary angiographic procedures in high-risk patients and remains a significant unmet need. In pre-clinical studies inorganic nitrate, which is chemically reduced in vivo to nitric oxide, is renoprotective
-
Anderson–Fabry disease management: role of the cardiologist Eur. Heart J. (IF 37.6) Pub Date : 2024-03-15 Maurizio Pieroni, Mehdi Namdar, Iacopo Olivotto, Robert J Desnick
Anderson–Fabry disease (AFD) is a lysosomal storage disorder characterized by glycolipid accumulation in cardiac cells, associated with a peculiar form of hypertrophic cardiomyopathy (HCM). Up to 1% of patients with a diagnosis of HCM indeed have AFD. With the availability of targeted therapies for sarcomeric HCM and its genocopies, a timely differential diagnosis is essential. Specifically, the therapeutic
-
Recombinant human soluble domain of CD39L3 and ticagrelor: cardioprotective effects in experimental myocardial infarction Eur. Heart J. (IF 37.6) Pub Date : 2024-03-15 Gemma Vilahur, Monika Radike, Pablo Sutelman, Soumaya Ben-Aicha, Manuel Gutiérrez, Laura Casaní, Daniel Hovdal, Emily L Ongstad, Anders Gabrielsen, Alberto Hidalgo, Ola Fjellström, Leif Carlsson, Lina Badimon
Background and Aims The ecto–nucleoside triphosphate diphosphohydrolases of the CD39 family degrade ATP and ADP into AMP, which is converted into adenosine by the extracellular CD73/ecto-5-nucleotidase. This pathway has been explored in antithrombotic treatments but little in myocardial protection. We have investigated whether the administration of solCD39L3 (AZD3366) confers additional cardioprotection
-
Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence Eur. Heart J. (IF 37.6) Pub Date : 2024-03-05 Nabil V Sayour, Ágnes M Paál, Pietro Ameri, Wouter C Meijers, Giorgio Minotti, Ioanna Andreadou, Antonella Lombardo, Massimiliano Camilli, Heinz Drexel, Erik Lerkevang Grove, Gheorghe Andrei Dan, Andreea Ivanescu, Anne Grete Semb, Gianluigi Savarese, Dobromir Dobrev, Filippo Crea, Juan-Carlos Kaski, Rudolf A de Boer, Péter Ferdinandy, Zoltán V Varga
Heart failure (HF) patients have a significantly higher risk of new-onset cancer and cancer-associated mortality, compared to subjects free of HF. While both the prevention and treatment of new-onset HF in patients with cancer have been investigated extensively, less is known about the prevention and treatment of new-onset cancer in patients with HF, and whether and how guideline-directed medical therapy
-
Atrial secondary tricuspid regurgitation: pathophysiology, definition, diagnosis, and treatment Eur. Heart J. (IF 37.6) Pub Date : 2024-03-05 Denisa Muraru, Luigi P Badano, Rebecca T Hahn, Roberto M Lang, Victoria Delgado, Nina C Wunderlich, Erwan Donal, Maurizio Taramasso, Alison Duncan, Philipp Lurz, Tom De Potter, José L Zamorano Gómez, Jeroen J Bax, Ralph Stephan von Bardeleben, Maurice Enriquez-Sarano, Francesco Maisano, Fabien Praz, Marta Sitges
Atrial secondary tricuspid regurgitation (A-STR) is a distinct phenotype of secondary tricuspid regurgitation with predominant dilation of the right atrium and normal right and left ventricular function. Atrial secondary tricuspid regurgitation occurs most commonly in elderly women with atrial fibrillation and in heart failure with preserved ejection fraction in sinus rhythm. In A-STR, the main mechanism
-
Leadless pacemakers at 5-year follow-up: the Micra transcatheter pacing system post-approval registry Eur. Heart J. (IF 37.6) Pub Date : 2024-03-01 Mikhael F El-Chami, Christophe Garweg, Nicolas Clementy, Faisal Al-Samadi, Saverio Iacopino, Jose Luis Martinez-Sande, Paul R Roberts, Claudio Tondo, Jens Brock Johansen, Xavier Vinolas-Prat, Yong-Mei Cha, Eric Grubman, Pierre Bordachar, Kurt Stromberg, Dedra H Fagan, Jonathan P Piccini
Background and Aims Prior reports have demonstrated a favourable safety and efficacy profile of the Micra leadless pacemaker over mid-term follow-up; however, long-term outcomes in real-world clinical practice remain unknown. Updated performance of the Micra VR leadless pacemaker through five years from the worldwide post-approval registry (PAR) was assessed. Methods All Micra PAR patients undergoing
-
Transcatheter treatment of the tricuspid valve: current status and perspectives Eur. Heart J. (IF 37.6) Pub Date : 2024-03-01 Francesco Maisano, Rebecca Hahn, Paul Sorajja, Fabien Praz, Philipp Lurz
Transcatheter tricuspid valve interventions (TTVI) are emerging as alternatives to surgery in high-risk patients with isolated or concomitant tricuspid regurgitation. The development of new minimally invasive solutions potentially more adapted to this largely undertreated population of patients, has fuelled the interest for the tricuspid valve. Growing evidence and new concepts have contributed to
-
Kidney replacement therapy: trends in incidence, treatment, and outcomes of myocardial infarction and stroke in a nationwide Scottish study Eur. Heart J. (IF 37.6) Pub Date : 2024-03-01 Peter J Gallacher, David Yeung, Samira Bell, Anoop S V Shah, Nicholas L Mills, Neeraj Dhaun
Background and Aims Patients with kidney failure have a higher risk of cardiovascular disease compared with the general population. Whilst temporal trends of myocardial infarction and stroke are declining in the general population, these have not been evaluated in patients with kidney failure. This study aimed to describe national trends in the incidence, treatment, and outcomes of myocardial infarction